Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Late-Stage CNS Drugs Key For Alkermes, But Early-Stage IL-2 Agonist Fascinates

Feb 28 2018

• By John Davis

Dublin — Dublin, where Alkermes is headquartered. • Source: Shutterstock

Related Content

Biogen Makes Lifecycle Gambit In Next-Gen MS Drug Deal With Alkermes

Nov 27 2017

Bristol Goes In Big On New Valentine Nektar

Feb 14 2018

Nektar/Bristol Deal May Shake Up Immuno-Oncology Landscape

Feb 15 2018

Related Companies

Bristol Myers Squibb Company

Nektar Therapeutics

Alkermes plc

Additional Topics

ImmunoOncology Research & Development Companies Business Strategies Neurology Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window